Vir Biotechnology (VIR) Price & Analysis

Compare

1,379 Followers

VIR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.16 - $14.45

Previous CloseN/A

Volume25.73M

Average Volume (3M)1.07M

Market Cap

$636.24M

Enterprise Value$105.77M

Total Cash (Recent Filing)$686.97M

Total Debt (Recent Filing)$93.41M

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Oct 30, 2025

EPS Estimate

-0.84

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding138,916,430

10 Day Avg. Volume1,075,373

30 Day Avg. Volume1,069,498

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.17

Enterprise Value/Revenue6.35

Enterprise Value/Gross Profit6.64

Enterprise Value/Ebitda-0.18

Forecast

1Y Price Target

$16.67

Price Target Upside263.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial StabilityVir ended 2Q25 with approximately $892M in cash and investments, providing financial stability and runway into mid-2027.

Oncology Pipeline ProgressVir’s oncology pipeline advanced with VIR-5525 initiating first-in-human dosing and joining VIR-5818 and VIR-5500 as active clinical programs.

Regulatory ApprovalsThe ECLIPSE program for chronic hepatitis delta has received Breakthrough Therapy and Fast Track designations in the U.S., and PRIME and Orphan Drug designations in the EU, which may streamline regulatory engagement.

Bears Say

Competitive PositioningPasritamig's safety profile could challenge VIR-5500's competitive positioning, with only 9% Grade 1 CRS at RP2D compared to VIR-5500's 25% low-grade CRS rate.

Dosing Schedule ChallengesThe Q6W dosing schedule for pasritamig could provide commercial convenience advantages over VIR-5500's current weekly dosing.

Vir Biotechnology News

Vir Biotechnology reports Q2 EPS (80c), consensus (72c)

“We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune...

18d ago

VIR

Vir Biotechnology enrolls first participant in ECLIPSE 3 trial

Vir Biotechnology (VIR) announced the enrollment of the first participant in ECLIPSE 3. All three trials in the...

19d ago

VIR

Vir Biotechnology enrolls first patient in ECLIPSE trial

Vir Biotechnology (VIR) announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial,...

25d ago

VIR

Vir Biotechnology’s Strategic Advancements and Strong Pipeline Drive Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, retaining the price target of...

17d ago

VIR

Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating

Vir Biotechnology, the Healthcare sector company, was revisited by a Wall Street analyst on August 6. Analyst Roanna...

17d ago

VIR

Vir Biotechnology’s Earnings Call Highlights Progress and Challenges

Vir Biotechnology, Inc. (($VIR)) has held its Q2 earnings call. Read on for the main highlights of the...

17d ago

VIR

Vir Biotechnology’s Strong Clinical Pipeline and Financial Position Reinforce Buy Rating

Analyst Joseph Stringer of Needham maintained a Buy rating on Vir Biotechnology, retaining the price target of $14.00....

18d ago

VIR

Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VIR stock, giving a Buy rating today....

18d ago

VIR

Vir Biotechnology Reports Q2 2025 Financial Results

Vir Biotechnology, Inc. ( ($VIR) ) has released its Q2 earnings. Here is a breakdown of the information...

18d ago

VIR

Vir Biotechnology Begins Phase 1 Trial for VIR-5525

Vir Biotechnology ( ($VIR) ) has provided an update. On July 24, 2025, Vir Biotechnology announced the dosing...

29d ago

VIR

Vir Biotechnology Begins Phase 1 Trial for VIR-5525

Vir Biotechnology ( ($VIR) ) has provided an update. On July 24, 2025, Vir Biotechnology announced the dosing...

1M ago

VIR

Vir Biotechnology doses first patient in VIR-5525 trial

Vir Biotechnology (VIR) announced that the first patient has been dosed in the company’s Phase 1 clinical trial...

1M ago

VIR

Insider Moves: Fastenal, Vir, Cipher, Verisign, HEICO

Insiders have been trading these 5 stocks: (($FAST)), (($VIR)), (($CIFR)), (($VRSN)) and (($HEI)). Here is a breakdown of...

1M ago

HEI

VIR

CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

AMC

BYD

VIR FAQ

What was Vir Biotechnology, Inc.’s price range in the past 12 months?

Vir Biotechnology, Inc. lowest stock price was $4.16 and its highest was $14.45 in the past 12 months.

What is Vir Biotechnology, Inc.’s market cap?

Vir Biotechnology, Inc.’s market cap is $636.24M.

When is Vir Biotechnology, Inc.’s upcoming earnings report date?

Vir Biotechnology, Inc.’s upcoming earnings report date is Oct 30, 2025 which is in 66 days.

How were Vir Biotechnology, Inc.’s earnings last quarter?

Vir Biotechnology, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.723 by -$0.077.

Is Vir Biotechnology, Inc. overvalued?

According to Wall Street analysts Vir Biotechnology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vir Biotechnology, Inc. pay dividends?

Vir Biotechnology, Inc. does not currently pay dividends.

What is Vir Biotechnology, Inc.’s EPS estimate?

Vir Biotechnology, Inc.’s EPS estimate is -0.84.

How many shares outstanding does Vir Biotechnology, Inc. have?

Vir Biotechnology, Inc. has 138,916,430 shares outstanding.

What happened to Vir Biotechnology, Inc.’s price movement after its last earnings report?

Vir Biotechnology, Inc. reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.723. Following the earnings report the stock price went down -14.37%.

Which hedge fund is a major shareholder of Vir Biotechnology, Inc.?

Currently, no hedge funds are holding shares in VIR

Vir Biotechnology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-46.22%

Trailing 12-Months

Asset Growth

-28.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. The company leverages its proprietary technology platforms, including monoclonal antibodies and T cell therapies, to develop innovative solutions against viral infections such as COVID-19, influenza, and hepatitis B. Vir's core products include investigational therapies aimed at harnessing the immune system to combat these diseases, with a strong emphasis on scientific research and development.

Vir Biotechnology (VIR) Earnings & Revenues

Historic Earnings Reports

VIR Company Deck

VIR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlights Vir Biotechnology's significant progress in their ECLIPSE program and T cell engager portfolio, alongside a strong financial position and reduced operating expenses. However, the company continues to face challenges with net losses and estimating the HDV patient population.View all VIR earnings summaries

VIR Stock 12 Month Forecast

Average Price Target

$16.67

▲(263.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","25":"$25","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,11,18,25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.03,7.027692307692308,9.025384615384615,11.023076923076923,13.02076923076923,15.018461538461537,17.016153846153845,19.013846153846153,21.01153846153846,23.00923076923077,25.006923076923076,27.004615384615384,29.002307692307692,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.03,5.9253846153846155,6.820769230769232,7.716153846153847,8.611538461538462,9.506923076923076,10.402307692307694,11.297692307692309,12.193076923076923,13.08846153846154,13.983846153846155,14.87923076923077,15.774615384615387,{"y":16.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.03,5.5661538461538465,6.102307692307693,6.638461538461538,7.174615384615384,7.71076923076923,8.246923076923077,8.783076923076923,9.319230769230769,9.855384615384615,10.391538461538461,10.927692307692308,11.463846153846152,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.27,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >